CELLphenomics is redefining cancer treatment by taking a functional approach to precision oncology in blood cancers. 

This cutting-edge science will facilitate drug development and enable pharmaceutical companies to get new therapies to patients faster.

CELLphenomics has developed a custom precision medicine platform that blends high-throughput flow cytometry with advanced automation and a streamlined analysis pipeline. This platform has been optimized to analyze drug sensitivity across many drug classes in primary patient samples. CELLphenomics high-throughput flow cytometry readout includes measures of apoptosis, proliferation, differentiation, and stemness. Additionally, CELLphenomics combines the data produced by its flow-cytometry platform with valuable patient clinical characteristics, allowing more complex analyses to be performed.

CELLphenomics' ex vivo services combines machine learning, automation and highthroughput screening directly on patient samples to help predict responses to potential therapies, and ultimately determine which drugs or drug combinations will be most effective for specific types of cancers. The end to end integrated technology platform conducts functional drug sensitivity screening to predict drug efficacy, toxicity profiling, target validation, enhance patient selection, and predict patient response.